Related Experiment Video
Updated: Nov 11, 2025
Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
Published on: April 6, 2015
Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody"
Jafar Sharifi1, Mohammad Reza Khirehgesh1, Bahman Akbari2,3
1Department of Medical Biotechnology, School of Medical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Abstract:
Targeted therapy is an effective and appropriate approach with low side effects in cancer therapy compared with other treatment approaches. Epidermal growth factor receptor, EGFR, is a favorable biomarker as targeted therapy because it overexpresses in several cancers. Monoclonal antibodies are common agents for targeted therapy. Nanobody is the smallest format of monoclonal antibodies with unique properties that include hiding epitope targeting, high stability, low production cost, and ease of connection to other components. The main challenge in targeted therapy by monoclonal antibodies is their immunogenicity due to their non-human nature. In this study, we designed, constructed, and evaluated a novel humanized anti- EGFR biparatopic nanobody, hu7CG2. The hu7CG2 was designed by grafting the complementarity-determining regions of two camelid anti- EGFR nanobodies known as 7C12 and EG2 to a universal scaffold and then connected with a glycine-serine linker. The results of antigen-binding activity and cell viability assays showed that the hu7CG2 inhibited the growth of EGFR overexpression tumor cells. The data showed that hu7CG2 might be a useful tool in the targeting and treatment of tumor cells.
Insights
A new humanized nanobody, hu7CG2, effectively targets and inhibits the growth of epidermal growth factor receptor (EGFR) overexpressing tumor cells. This novel targeted therapy approach shows promise for cancer treatment with potentially low side effects.
Area of Science:
- Oncology
- Biotechnology
- Immunology
Background:
- Targeted therapy offers an effective cancer treatment with fewer side effects than traditional approaches.
- Epidermal growth factor receptor (EGFR) is a key biomarker for targeted therapy due to its overexpression in various cancers.
- Nanobodies, small antibody formats, possess unique properties like high stability and low cost, but immunogenicity is a challenge for monoclonal antibodies.
Purpose of the Study:
- To design, construct, and evaluate a novel humanized biparatopic nanobody targeting EGFR.
- To assess the efficacy of the humanized nanobody in inhibiting the growth of EGFR-overexpressing tumor cells.
Main Methods:
- Designed and constructed a humanized anti-EGFR biparatopic nanobody (hu7CG2) by grafting complementarity-determining regions from camelid nanobodies onto a universal scaffold.
- Linked nanobody fragments using a glycine-serine linker.
- Evaluated antigen-binding activity and cell viability assays.
Main Results:
- The hu7CG2 nanobody demonstrated antigen-binding activity.
- Cell viability assays confirmed that hu7CG2 inhibited the growth of EGFR-overexpressing tumor cells.
- The humanized nanobody showed potential as a therapeutic agent.
Conclusions:
- The novel humanized biparatopic nanobody, hu7CG2, is effective in inhibiting EGFR-overexpressing tumor cells.
- hu7CG2 represents a promising tool for targeted cancer therapy.
- This approach may offer a low-side-effect alternative in cancer treatment.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
